Claim Amendments

Please amend the claims as shown below.

1. (currently amended) A crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of ~~another~~ other famciclovir crystalline forms ~~form~~.
2. (previously presented) The crystalline solid famciclovir of claim 1, further characterized by a XRD pattern with peaks at 8.2, 10.4, 14.5, 17.0, 17.7, 19.5, 20.6, 21.1, 22.3, 23.0, 23.9, 24.4, 25.6, 26.5, 28.6, 29.0 and 32.6 ± 0.2 deg. 2θ.
3. (previously presented) The crystalline solid famciclovir of claim 2, wherein the XRD pattern is as substantially depicted in Fig. 1.
4. (canceled)
5. (currently amended) ~~The crystalline~~ Crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ ~~of any one of claims 1-3~~, wherein the crystalline solid famciclovir contains less than about 5% wt of form II.
6. (previously presented) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 1% wt of another famciclovir crystalline form.
7. (previously presented) The crystalline solid famciclovir of claim 5, wherein the crystalline solid famciclovir contains less than about 1% wt of form II.
8. (previously presented) A crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
9. (previously presented) The crystalline solid famciclovir of claim 8, further characterized by the XRD pattern having peaks at 8.3, 14.6, 17.8, 19.7, 20.7, 21.2, 24.5 and 25.6 ± 0.2 deg. 2θ.
10. (previously presented) The crystalline solid famciclovir of claim 9, wherein the XRD pattern is as substantially depicted in Fig. 2.
11. (canceled)
12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (previously presented) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

    a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether; and

    b) isolating the crystalline solid famciclovir of claim 1.

19. (previously presented) A crystalline solid famciclovir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir is prepared by triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether.

20-30. (canceled)

31. (previously presented) A process for preparing a mixture of crystalline solid famciclovir characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, and crystalline solid famciclvir characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

    a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,

    b) cooling the solution, and

    c) isolating the mixture of the crystalline solid famciclovir characterized by the XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, and the crystalline solid famciclovir characterized by the XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

32-34. (canceled)

35. (previously presented) A process of preparing a crystalline solid famciclovir monohydrate, comprising the steps of:

a) providing a solution of famciclovir in an ethanol/water mixture, DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and/or isopropyl alcohol/water mixture; and

b) cooling the solution; and

c) isolating the crystalline solid famciclovir monohydrate.

36. (canceled)

37. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient.

38. (currently amended) ~~The~~ A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient ~~of claim 37~~, wherein the crystalline solid famciclovir of claim 1 contains less than about 1% wt of another famciclovir crystalline form.

39. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient.

40. (currently amended) ~~The~~ A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient ~~of claim 39~~, wherein the crystalline solid famciclovir of claim 8 contains less than about 1% wt of another famciclovir crystalline form.

41-51. (canceled)

52. (new) A method of treating a human in need of treatment with famciclovir comprising administering to the human the pharmaceutical composition of any one of claims 37-40.

53. (new) Crystalline solid famciclovir methanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

54. (new) The crystalline solid famciclovir solvate of claim 53, further characterized by the XRD pattern having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

55. (new) The crystalline solid famciclovir solvate of claim 54, wherein the XRD pattern is as substantially depicted in Fig. 3.

56. (new) The crystalline solid famciclovir solvate of claim 53, containing less than about 5% wt of another famciclovir crystalline form.

57. (new) Crystalline solid famciclovir ethanol solvate, characterized by a XRD pattern having peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

58. (new) Crystalline solid famciclovir methanol solvate.

59. (new) Crystalline solid famciclovir ethanol solvate.

60. (new) A process for preparing crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating crystalline solid famciclovir methanol or ethanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ, to about 40° C to about 90° C; and

b) isolating the crystalline solid famciclovir form I.

61. (new) The process of claim 60, wherein the heating of the crystalline solid famciclovir methanol or ethanol solvate is performed at a temperature of about 60° C to about 70° C.

62. (new) A process for preparing crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating famciclovir monohydrate to about 40° C to about 80° C; and

b) isolating the crystalline solid famciclovir form I.

63. (new) The process of claim 62, wherein step a) is performed by heating a mixture of the famciclovir monohydrate and crystalline solid famciclovir form I characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

64. (new) The process of claim 62, wherein the heating of famciclovir monohydrate is performed at a temperature of about 60° C to about 70° C.

65. (new) A process for preparing crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, to about 40° C to about 90° C; and

b) isolating the crystalline solid famciclovir form I.

66. (new) The process of any one of claims 60, 62 and 65, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of other famciclovir crystalline forms.

67. (new) The process of any one of claims 60, 62 and 65, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir form II.

68. (new) The process of claim 66, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of other famciclovir crystalline forms.

69. (new) The process of claim 68, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir form II.

70. (new) A process for preparing a mixture of crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, and crystalline solid famciclvir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

c) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,

d) cooling the solution, and

e) isolating the mixture of the crystalline solid famciclovir form II, and the crystalline solid famciclovir form I.

71. (new) A process for preparing the crystalline solid famciclovir methanol solvate of claim 53, comprising the steps of:

a) triturating an anhydrous famciclovir in methanol; and

b) isolating the crystalline solid famciclovir methanol solvate.

72. (new) A process of preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ and containing less than about 5% wt of another famciclovir crystalline form, comprising the steps of:

a) triturating an anhydrous famciclovir in ethanol; and

b) isolating the mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and the crystalline solid famciclovir form I.

73. (new) A process for preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 57 and crystalline solid famciclovir monohydrate, comprising the steps of:

a) triturating anhydrous famciclovir in an ethanol/water mixture; and

b) isolating the mixture of the crystalline solid famciclovir ethanol solvate and crystalline solid famciclovir monohydrate.

74. (new) A solid pharmaceutical composition comprising a crystalline solid famciclovir methanol or ethanol solvate of claim 53 or 57 and a pharmaceutically-acceptable excipient,

wherein the crystalline solid famciclovir methanol or ethanol solvate contains less than about 5% wt of another famciclovir crystalline form.

75. (new) The solid pharmaceutical composition of claim 74, wherein the crystalline solid famciclovir methanol or ethanol solvate contains less than about 1% wt of another famciclovir crystalline form.

76. (new) A method of treating a human in need of treatment with famciclovir administering to the human the pharmaceutical composition of any one of claims 74-75.

77. (new) The crystalline solid famciclovir ethanol solvate of claim 57, further characterized by the XRD pattern having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

78. (new) The crystalline solid famciclovir methanol solvate of claim 56, containing less than about 1% wt of another famciclovir crystalline form.

79. (new) A process for preparing the crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ and containing less than about 5% wt of another famciclovir crystalline form, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, acetone, THF, diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture and dimethylacetamide,

b) cooling the solution, and

c) isolating the crystalline solid famciclovir form I.

80. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of other famciclovir crystalline forms.

81. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir form II.

82. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of other famciclovir crystalline forms.

83. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir form II.